Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncophage Effect In Subgroup Supports Continued Development, Firm Says

Executive Summary

Antigenics is seeing salvation for its Oncophage cancer vaccine based on signs of a clinically significant improvement in a subgroup of patients with a better prognosis in its Phase III renal cell carcinoma trial

You may also be interested in...



Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition

A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said

Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition

A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said

Lung Cancer Immunotherapies Show Promise, But New Directions Needed

Results from two cancer vaccine studies suggest that lung cancer patients may benefit from immunotherapy, David Carbone (Vanderbilt-Ingram Cancer Center) concluded at the American Society of Clinical Oncology's annual meeting June 4 in Atlanta

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel